Group 1: Innovative Drug Sector - The innovative drug concept stocks have generally risen, with notable increases in companies such as CSPC Pharmaceutical Group (up 6.34%), WuXi Biologics (up 5.54%), and Innovent Biologics (up 5.15%) due to significant collaborations announced in early 2026, including a $18.5 billion partnership between CSPC and AstraZeneca [1] - Junshi Biosciences has seen a rise of over 9%, with a cumulative increase of over 24% this month, following an exclusive commercialization agreement for its PD-1 antibody in Japan [1] - Baijie Pharmaceutical has surged over 10%, with its stock price increasing more than 440% from its IPO price of HKD 26.38 [1] Group 2: AI and Technology Sector - Yunzhisheng has increased by over 9%, supported by a report highlighting its strong industry barriers and partnerships with top hospitals, covering 40% of the top 100 hospitals in China [2] - Wanka Yilian has risen over 10%, with a year-to-date increase of over 90%, following Alibaba's announcement of its AI strategy transition [2] Group 3: CRO Sector - CRO concept stocks have shown strong performance, with companies like Vyaire Medical (up 6.14%) and WuXi Biologics (up 5.54%) leading the gains, as projections indicate a significant increase in net profits for WuXi AppTec and Tigermed in 2025 [2] - The global biopharmaceutical investment data is expected to recover in 2025, with a projected growth rate of 2.7% globally and 6.4% in China, driven by a hot market for innovative drug development [2] Group 4: Film and Entertainment Sector - Film concept stocks have risen, with companies like Damai Entertainment (up 8.16%) and Maoyan Entertainment (up 4.8%) benefiting from the pre-sale of new films for the 2026 Spring Festival [3] Group 5: Financial Performance and Forecasts - China National Nuclear Corporation International has seen a nearly 14% increase, with a forecasted revenue of at least CNY 2.46 billion for 2025, representing a year-on-year growth of at least 33.6% [3] - Pop Mart has increased by over 4.5%, with a projection of over 400 million global sales of its products in 2025 [4] Group 6: US Market Highlights - In the US market, companies like Lexin (up 8.54%) and Credo Technology (up 10.78%) have shown strong performance, driven by positive market conditions and significant agreements [5] - STMicroelectronics has risen by 8.91% following a multi-billion dollar agreement with Amazon to advance semiconductor technology [5] - Li Auto has seen a decline of 3.27% after a downgrade from Morgan Stanley, reflecting concerns about the Chinese automotive market's performance in 2026 [6]

Core Viewpoint - The company, Lifan Pharmaceutical, has received the acceptance notice for the listing application of Finerenone raw material from the National Medical Products Administration, indicating progress in its product development and potential market entry [1] Group 1: Product Information - Finerenone is a novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) [1] - The formulation is intended for adult patients with chronic kidney disease associated with type 2 diabetes, aiming to reduce the risk of sustained decline in eGFR and end-stage renal disease [1]

Core Viewpoint - Reborn Bio-B (06938) shares rose over 5%, currently up 5.62% at HKD 72.45, with a trading volume of HKD 6.483 million, following the announcement of the II phase clinical trial approval for its self-developed RBD5044 injection by the National Medical Products Administration of China [1] Company Summary - RBD5044 is a siRNA drug targeting APOC3, a protein synthesized primarily in the liver that plays a crucial role in lipid metabolism [1] - The drug aims to address complications associated with hypertriglyceridemia, providing a treatment option for managing dyslipidemia [1] Industry Summary - According to Guosheng Securities (002670), small nucleic acid drugs are entering a robust global development phase, transitioning from technical validation to clinical realization and accelerated commercialization [1] - A total of 23 small nucleic acid drugs have been approved globally, covering various technical directions such as siRNA, ASO, and aptamers [1] - Although no products have been launched domestically yet, the number of research pipelines ranks second to the U.S., covering multiple therapeutic areas including hyperlipidemia, hypertension, hepatitis B, kidney diseases, muscular diseases, and obesity [1] - Significant collaborations have emerged, such as the over USD 9 billion partnership between WuXi AppTec and Novartis, and a USD 2 billion platform licensing deal between Reborn Bio and Boehringer Ingelheim, indicating a positive development trend in the industry [1]

立方制药公告称，近日收到国家药监局下发的非奈利酮原料药上市申请《受理通知书》。非奈利酮是新 型盐皮质激素受体拮抗剂，制剂用于2型糖尿病相关慢性肾病成人患者。截至公告日，该品种原料药登 记备案企业中5家登记状态为"A"，其余为"I"。此次申请获受理，意味着品种进入注册审评阶段，对近 期业绩无重大影响，若顺利通过审评，将丰富公司原料药产品管线。但注册批准结果和时间不确定，投 资者需注意风险。 ...

Core Viewpoint - Baoyi Pharmaceutical-B (02659) has seen its stock price rise over 440% from its IPO price of 26.38 HKD, reaching a high of 143 HKD, indicating strong market interest and potential for future growth [1][5]. Group 1: Company Overview - Baoyi Pharmaceutical has developed three core products: KJ017, a recombinant hyaluronidase for large-volume subcutaneous administration; KJ103, an IgG degrading enzyme with "best-in-class" potential for autoimmune diseases; and SJ02, a long-acting follicle-stimulating hormone for assisted reproduction [1][5]. - These products are in various stages of commercialization, new drug application registration, or late-stage clinical trials in China, signaling a transition from pure research to commercialization for Baoyi Pharmaceutical [1][5]. Group 2: Financial Outlook - According to a report from Xiniu Securities, Baoyi Pharmaceutical has established a clear commercialization model and timeline, with expectations that its products will start contributing significantly to revenue by 2026, primarily from KJ017 and SJ02 [1][5]. - KJ103, which is aimed at desensitization in kidney transplantation, is projected to begin generating revenue in 2027, while its applications for GBS and anti-GBM diseases will contribute at a later date [1][5].

Core Viewpoint - The innovative drug concept stocks have generally risen in the morning session, indicating positive market sentiment towards this sector [1][2]. Group 1: Stock Performance - CSPC Pharmaceutical Group (01093) increased by 7.16%, trading at HKD 10.48 [1][2]. - WuXi Biologics (02269) rose by 5.54%, with a price of HKD 40.36 [1][2]. - CanSino Biologics-B (02162) saw a gain of 5.45%, priced at HKD 60.95 [1][2]. - Innovent Biologics (01801) experienced a 5.15% increase, trading at HKD 89.8 [1][2]. - Zai Lab (09688) climbed by 4.9%, with shares priced at HKD 14.76 [1][2].

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index (HSSCID) has surged by 4.32%, while the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) has increased by 3.50%, marking a three-day consecutive rise [1] - Innovent Biologics has entered into a global strategic collaboration with Eli Lilly to advance the development of new drugs in oncology and immunology, with a deal size exceeding expectations [1] - Under the agreement, Innovent will lead the research and development of related projects from drug discovery to clinical proof of concept in China, while Eli Lilly will obtain exclusive development and commercialization rights outside Greater China [1] Group 2 - According to Zhongyou Securities, although the innovative drug sector has experienced short-term fluctuations due to funding issues, the global participation trend has been fully reflected in 2025 [2] - Domestic new drugs are transitioning from early research to a phase of efficiency, indicating that the innovative drug sector is expected to enter a harvest period in the medium term [2] - The E Fund Hong Kong Stock Connect Innovative Drug ETF closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [2]

本文编选自"国家医保局"，智通财经编辑：李佛。 本次接续采购中选结果预计将于2026年3月底落地实施，采购周期至2028年底。较长的采购周期能够让 患者持续获益，为行业带来稳定的生产和销售预期，促进国家组织药品集采成果进一步巩固。 智通财经APP获悉，2026年2月9日，1-8批国家集采药品新一轮接续采购开标产生拟中选结果。本次接 续采购涉及1-8批国家集采的316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系 统、呼吸系统、消化系统等26个治疗领域。全国5.1万家医药机构参加报量，共1091家国内外企业的 4623个产品参与投标，1020家企业的4163个产品获得拟中选资格。 本次接续采购是国家组织集采的化学药品首次开展全国范围统一接续，由江苏、河南、广东三省医保局 联合牵头，各省份全部参与，实现了采购规则规范统一。企业只需在线投标一次，中选即可实现全国销 售，大幅减轻投标成本。主要有以下特点：一是企业参与积极性高，中选产品丰富多样。具备投标资格 的企业绝大多数参与投标报价，整体中选率高达93%。每个品种平均14家企业中选，市场供应多元，临 床选择丰富。二是临床需求匹配度高，患者用药总体稳定 ...

Core Viewpoint - The innovative pharmaceutical sector is experiencing a significant rise, with multiple companies reporting substantial stock increases due to recent high-profile collaborations and a positive outlook for revenue growth in the industry [1] Group 1: Stock Performance - Innovative drug concept stocks are generally rising, with notable increases: - CSPC Pharmaceutical Group (01093) up 7.16% to HKD 10.48 - WuXi Biologics (02269) up 5.54% to HKD 40.36 - CanSino Biologics-B (02162) up 5.45% to HKD 60.95 - Innovent Biologics (01801) up 5.15% to HKD 89.8 - Zai Lab (09688) up 4.9% to HKD 14.76 [1] Group 2: Collaborations and Partnerships - Significant collaborations have been announced in 2026, including: - CSPC Pharmaceutical Group's partnership with AstraZeneca worth up to USD 18.5 billion - Rongchang Biologics' agreement with AbbVie valued at USD 5.6 billion - Various innovative drug export formats are emerging, such as "single product licensing" and "technology platform + heavyweight single product" [1] Group 3: Industry Outlook - According to Kaiyuan Securities, the revenue growth in innovative drugs is accelerating, with over 70% of companies expected to achieve positive revenue growth by 2025 - The innovative drug sector has seen a correction over the past two quarters, but long-term prospects indicate that many quality stocks offer attractive valuation opportunities - It is recommended to increase allocation in this sector, focusing on companies with established overseas operations and high clinical data performance [1]

Core Viewpoint - The innovative drug sector is experiencing a significant rise, with multiple companies reporting substantial stock increases and notable collaborations in 2026, indicating a robust growth phase for the industry [1] Group 1: Stock Performance - Companies such as CSPC Pharmaceutical (01093) saw a stock increase of 7.16%, trading at HKD 10.48; WuXi Biologics (02269) rose by 5.54% to HKD 40.36; CanSino Biologics-B (02162) increased by 5.45% to HKD 60.95; Innovent Biologics (01801) gained 5.15% to HKD 89.8; and Zai Lab (09688) rose by 4.9% to HKD 14.76 [1] Group 2: Collaborations and Partnerships - Significant collaborations have emerged in 2026, including CSPC Pharmaceutical's partnership with AstraZeneca valued at up to USD 18.5 billion, and Rongchang Biopharmaceutical's agreement with AbbVie worth USD 5.6 billion, showcasing various innovative drug export models [1] Group 3: Industry Growth and Outlook - According to Open Source Securities, the revenue growth in the innovative drug sector is accelerating, with over 70% of companies expected to achieve positive revenue growth by 2025; the sector has undergone a correction over the past two quarters, but long-term prospects for quality stocks appear favorable [1] - The firm recommends increasing allocation to the innovative drug sector, focusing on companies with established overseas operations and high clinical data quality, which are likely to have better export probabilities [1]